SE447257B - PROCEDURE FOR THE PREPARATION OF N- (2-PYRIMIDINYL) -PIPERAZINYLALKYL-AZASPIROAL CONDION - Google Patents
PROCEDURE FOR THE PREPARATION OF N- (2-PYRIMIDINYL) -PIPERAZINYLALKYL-AZASPIROAL CONDIONInfo
- Publication number
- SE447257B SE447257B SE8600174A SE8600174A SE447257B SE 447257 B SE447257 B SE 447257B SE 8600174 A SE8600174 A SE 8600174A SE 8600174 A SE8600174 A SE 8600174A SE 447257 B SE447257 B SE 447257B
- Authority
- SE
- Sweden
- Prior art keywords
- pyrimidinyl
- formula
- mol
- aza
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
10 447 257 spiroammoniumhalider i närvaro av en bas utan föregående bildning av spiroglutarimidmetallsaltet (1). 10 447 257 spiroammonium halides in the presence of a base without precedent formation of the spiroglutarimide metal salt (1).
Föreliggande uppfinning avser närmare bestämt ett för- farande för framställning av N-(2-pyrimidinyl)piperazinyl- alkylazaspiroalkandioner med formeln 0 f-g Iíïš \ (IV) vari n är 1 eller 2 och t är 4 eller 5, vilket förfarande innebär att man kondenserar en kvaternär spiroammonium- halidförening med formeln Clfmèh l 2; (I) 19' ll vari n är 1 eller 2 och X är klor, brom eller jod, med en spiro-substituerad glutarimid med formeln 0 (CB2)t -g ° vnrí L är 4 vllbr Û, i Väscniliqon vkvimolärn proportioner i ett vätskeformigt reaktionsmedium i närvaro av en kraftig 447 257 hus, såsom naLriumkarbonat, kaliumkarbonat eller liknande.More particularly, the present invention relates to a process for the preparation of N- (2-pyrimidinyl) piperazinyl- alkyl azaspiroalkanediones of the formula 0 f-g Iíïš \ (IV) wherein n is 1 or 2 and t is 4 or 5, which method involves condensing a quaternary spiroammonium halide compound of the formula Clfmèh l 2; (IN) 19 ' ll wherein n is 1 or 2 and X is chlorine, bromine or iodine, with a spiro-substituted glutarimide of the formula 0 (CB2) t -g ° vnrí L is 4 vllbr Û, in Väscniliqon vkvimolärn proportions in a liquid reaction medium in the presence of a strong 447 257 houses, such as sodium carbonate, potassium carbonate or the like.
Kondensutíonon av un kvatornär spiroammoniumhalidförening med formel I med en glutarimid med formel V utförs således i det reaktionsinerta vätskeformiga mediet i närvaro av en kraftig bas, såsom en alkalimetalloxid, -hydroxid, -amid, ~alkoholat eller ~karbonat, varvid natriumkarbonat och kaliumkarbonat i synnerhet föredras. Vätskeformiga reak- tionsmedier, som kokar inom intervallet 800-160OC föredras, varvid reaktionen lämpligen utförs vid det valda mediets kokpunkt. Lämpliga reaktionsinerta medier innefattar di- metylformamid liksom flytande kolväten, kolvätenitriler, kolväteetrar och alkanoler, såsom xylen, acetonitril, di- butyleter, isopropanol, n-butanol och liknande. Lämpliga reaktionstider sträcker sig från 2 till 24 timmar, varvid reaktionens varaktighet i viss utsträckning beror på den valda temperaturen och det valda reaktionslösningsmedlet.Condensation of a quaternary spiroammonium halide compound of formula I with a glutarimide of formula V is thus performed in the reaction-inert liquid medium in the presence of a strong base, such as an alkali metal oxide, hydroxide, amide, ~ alcoholate or ~ carbonate, whereby sodium carbonate and potassium carbonate is particularly preferred. Liquid reactions media boiling in the range 800-160 ° C are preferred, wherein the reaction is conveniently carried out at the selected medium boiling point. Suitable reaction inert media include di methylformamide as well as liquid hydrocarbons, hydrocarbon nitriles, hydrocarbon ethers and alkanols such as xylene, acetonitrile, di- butyl ether, isopropanol, n-butanol and the like. Suitable reaction times range from 2 to 24 hours, wherein the duration of the reaction depends to some extent on it the selected temperature and the selected reaction solvent.
En föredragen utföringsform av föreliggande uppfinning av- ser ett förfarande för framställning av 8-rÄ-K¶-(2-pyrimi- dinyl)-1-piperazinyi]butyl]-8-azaspiro[§.É]dekan-7,9-dion med formeln -wazn-u _ , A ° (IVI) och eventuellt hydrokloriden därav, vilket förfarande utmärks av att man kondenserar en spiro- -glutarimid med formeln U e 447 257 4 med en kvaternär spiroammoniumhalid med formeln 9 - //"¶ B: ® (In) i ett vätskeformigt reaktionsmedium i närvaro av en kraftig bas. Företrädesvis utförs denna reaktion i di- metylformamid i närvaro av kaliumkarbonat. Den erhållna produkten omsättes eventuellt med klorvätesyra för om- vandling av den fria basen till hydrokloridsaltet.A preferred embodiment of the present invention see a process for the preparation of 8-r dinyl) -1-piperazinyl] butyl] -8-azaspiro [§.É] decane-7,9-dione with the formula -wazn-u _, A ° (IVI) and optionally the hydrochloride thereof, which process is characterized by condensing a spiro -glutarimide of the formula U e 447 257 4 with a quaternary spiroammonium halide of the formula 9 - // "¶ B: ® (In) in a liquid reaction medium in the presence of a powerful bass. Preferably, this reaction is carried out in methylformamide in the presence of potassium carbonate. The obtained the product is optionally reacted with hydrochloric acid to convert conversion of the free base to the hydrochloride salt.
Uppfinningen åskådlíggörs närmare medelst följande utförings- exempel, vari temperaturangivelserna avser Celsiusgrader.The invention is further illustrated by the following embodiments. examples, in which the temperature indications refer to degrees Celsius.
Exempel 1 8-(2-pyrimidinyl)-8-aza-5~azoniaspiro¿Ä.5]dekan-klorid ”w Fun c19 2- egt En blandning av 32,8 g (0,2 mol) l-(2-pyrimidinyl)piper- azin, 76,2 q (0,6 mol) 1,4-diklorbutan och 44,5 g (0,42 mol) finpulvriserat natriumkarbonat i 300 ml acetonitríl omrördes och áterloppskokades under 12 timmar. Den varma reaktionsblandningen filtrerades och filterkakan tvättades med 50-100 ml varm acetonitril. De kombinerade filtraten hölls vid rumstemperatur till dess kristallisation inträdde, varefter blandningen kyldes och filtrerades och det till- varatagna materialet tvâttades med aceton för erhållande av 8-(2-pyrimidinyl)-8-aza-5-azoniaspiroll.5]dekanklorid (ut- byte 70-90%). Detta material var hygroskopiskt, och gav efter torkning i vakuum vid rumstemperatur monohydratformen, som 447 257 smälte vid ca 90°C och som vid fortsatt torkning i vakuum vid 90° under flera timmar gav den vatten- fria produkten med en smältpunkt av ca 2l0°.Example 1 8- (2-Pyrimidinyl) -8-aza-5-azoniaspiro [5] decan chloride ”W Fun c19 2- egt A mixture of 32.8 g (0.2 mol) of 1- (2-pyrimidinyl) piperine azine, 76.2 g (0.6 mol) of 1,4-dichlorobutane and 44.5 g (0.42) mol) finely powdered sodium carbonate in 300 ml of acetonitrile was stirred and refluxed for 12 hours. The hot the reaction mixture was filtered and the filter cake was washed with 50-100 ml of hot acetonitrile. The combined filtrates kept at room temperature until crystallization occurred, after which the mixture was cooled and filtered and it was added The material was washed with acetone to give 8- (2-pyrimidinyl) -8-aza-5-azoniaspirol.5] decan chloride (excl. byte 70-90%). This material was hygroscopic, and yielded drying in vacuo at room temperature the monohydrate form, which 447 257 melted at about 90 ° C and as with continued drying in vacuum at 90 ° for several hours gave the aqueous free product with a melting point of about 210 °.
Exemgel 2 8-(2-pyrimidinyl)-8-aza-5-azoniaspiroll.S7dekan-bromid \/_ C/>_< /C';\__ Omsättning av 1-(2-pyrimidiny1)piperazin och 1,4-dibrombutan - En blandning av 32,8 g (0,2 mol) 1-(2-pyrimidinyl)piperazin, 108 g (0,5 mol) 1,4-dibrombutan och 21,2 g (0,2 mol) finpulv- riserat natriumkarbonat i 400 ml isopropanol omrördes och återloppskokades under 16 timar. Den varma reaktionsbland- ningen filtrerades och efter att ha fått stå vid rumstempe- ratur gav filtratet 50,3 g (84 % utbyte) produkt. Kristalli- sation av detta material ur isopropanol gav analytiskt ren 8- -(2-pyrimidinyl)-8-aza-5-azoniaspiroll.§7dekan-bromid med smäicpunkten 241,5 - 24z,s° (korr.).Example 2 8- (2-Pyrimidinyl) -8-aza-5-azoniaspirol.Sdecane bromide \ / _ C /> _ </ C '; \ __ Reaction of 1- (2-pyrimidinyl) piperazine and 1,4-dibromobutane - A mixture of 32.8 g (0.2 mol) of 1- (2-pyrimidinyl) piperazine, 108 g (0.5 mol) of 1,4-dibromobutane and 21.2 g (0.2 mol) of fine powder The sodium carbonate in 400 ml of isopropanol was stirred and refluxed for 16 hours. The hot reaction mixture the filtration was filtered and after standing at room temperature The filtrate gave 50.3 g (84% yield) of product. Crystalline conversion of this material from isopropanol gave analytically pure 8- - (2-pyrimidinyl) -8-aza-5-azoniaspirole.§7 decane bromide with melting points 241.5 - 24z, s ° (corr.).
Br() Analys Ber. för C12H19N4'Br: C 48,17 H 6,40 N 18,72 Br 26,71 % Funnet: C 48,39 H 6,53 N 18,64 Br 26,60 % Omsättning av l-(2-pyrimidinyl)piperazin och 1,4-diklorbutan - En blandning av 16,4 g (0,1 mol) 1-(2-pyrhnidinyl)piperazin, 23,8 g (0,19 mol) 1,4-diklorbutan, 30,8 g (0,25 mol) natrium- karbonatnmrügdrat och 44,6 g (0,375 mol) kalfilünxndd 1 150 ml isopc- panol omrördes och återloppskokades under 8 timmar. Den varma 447 257 reaktionsblandningen filtrerades och olösligt material tvåttades med varm isopropanol. Koncentrering av de kom- binerade filtraten under reducerat tryck och tritureríng av det resterande materialet med aceton gav 8-(2-pyrimidinyl) -8-aza-5-azoniaspiro[1.§7dekan-bromid i utbyten av S0-90%.Br () Analysis Ber. for C 12 H 19 N 4 · Br: C 48.17 H 6.40 N 18.72 Br 26.71% Found: C 48.39 H 6.53 N 18.64 Br 26.60% Reaction of 1- (2-pyrimidinyl) piperazine and 1,4-dichlorobutane - A mixture of 16.4 g (0.1 mol) of 1- (2-pyrimidinyl) piperazine, 23.8 g (0.19 mol) of 1,4-dichlorobutane, 30.8 g (0.25 mol) of sodium carbonate monohydrate and 44.6 g (0.375 moles) of calcium panol was stirred and refluxed for 8 hours. The hot 447 257 the reaction mixture was filtered and insoluble material washed with hot isopropanol. Concentration of the combined the filtrates under reduced pressure and trituration of the remaining material with acetone gave 8- (2-pyrimidinyl) -8-aza-5-azoniaspiro [1.§7decane bromide in yields of SO-90%.
Exemgel 3 3-(2~pyrimidinyl)-3-aza-6-azoniaspirolä.åïundekan-klcrid -- , ae 'Lé Omsättning av 16,4 g (0,1 mol) 1-(2-pyrimidinyl)piperazin, 28,2 g (0,2 mol) l,5~diklorpentan och 21,2 g (0,2 mol) natri- umkarbonat i 300 ml isopropanol enligt förfarandet i exempel2 gav den i rubriken angivna föreningen i form av dess hydrat §gB¿ 270°C (sönderdelning) Elementantalvs: Beräknat för C13H2lN4Cl.0,75 H20: C 55,3l% H 8,03% N l9,85% H20 4,79% Funnet: C 55,50% H 7,87% N l9,54% H20 4,36% Strukturen har bekräftats medelst IR-, PMR-, MS- och CMR- analys.Exemgel 3 3- (2-Pyrimidinyl) -3-aza-6-azoniaspiroleadeecane chloride -, ae 'Lé Reaction of 16.4 g (0.1 mol) of 1- (2-pyrimidinyl) piperazine, 28.2 g (0.2 mol) of 1,5-dichloropentane and 21.2 g (0.2 mol) of sodium carbonate in 300 ml of isopropanol according to the procedure of Example 2 gave the title compound as its hydrate §GB¿ 270 ° C (dec.) Elemental number: Calculated for C13H21N4Cl.0.75 H2O: C 55.3l% H 8.03% N 19.85% H 2 O 4.79% Found: C 55.50% H 7.87% N 19.54% H 2 O 4.36% The structure has been confirmed by IR, PMR, MS and CMR analysis.
Exemgel 4 3-(2~pyrimidinyl)-3-aza-6-azoniaspiro/É.Sfundekan-bromid “šaí/BO n: En blandning av 24,6 g (0,l5 mol) l-(2-pyrimidinyl)piperazin, 100 g (0,43 mol) l,5-dibrompentan och 31,8 g (0,3 mol) pulvri- serat natriumkarbonat i 400 ml isopropanol àterloppskokades 18 timmar och fíltrerades därefter. Efter att ha fått stå gav det .-. ~> m.. 447 257 kylda filtratet 44,1 g (94 3 utbyte) produkt med smältpunkten 225 ~ 230°. Kristallisation ur isopropanol gav analytiskt ren 3-(2-pyrimidinyl)-3-aza-6-azoniaspirofiš.5]undekan-bromid med smaltpunkten 232 - 233%.Exemgel 4 3- (2-Pyrimidinyl) -3-aza-6-azoniaspiro [E. Fundecane bromide Šaí / BO n: A mixture of 24.6 g (0.5 mol) of 1- (2-pyrimidinyl) piperazine, 100 g (0.43 mol) of 1,5-dibromopentane and 31.8 g (0.3 mol) of powder free serate sodium carbonate in 400 ml of isopropanol was refluxed 18 hours and was then filtered. After being allowed to stand, it gave .-. ~> m .. 447 257 cooled filtrate 44.1 g (94 3 yield) of product with melting point 225 ~ 230 °. Crystallization from isopropanol gave analytically pure 3- (2-pyrimidinyl) -3-aza-6-azoniaspiro š š.5] undecane bromide with melting point 232 - 233%.
Analys Ber. för C13H2lN4-Br: C 49,85 H 6,76 N 17,89 Br 25,51 % Funnet: C 50,03 H 6,87 N 17,84 Br 25,44 % Exemgel 5 8-[Ä-Å2-(2-pyrimidinyl)-l-piperazinylf-buty17-8-azaspiro- ¿§.§Zdekan-7,9~dion o N'°3(cx)cH-u ~< > .z 22 z U R o Omsättning i n-butanol - En blandning av 7,5 g (0,045 mol) 3,3-tetrametylenglutarimid, 15,4 g (0,045 mol) 8-(2-pyrimi- dinyl)-8-aza-5-azoniaspiroll.åydekan-bromid och 6,2 g (0,045 mol) kaliumkarbonat i 250 ml n-butanol âterloppskokades 21 timmar, filtrerades och indunstades till torrhet. Det reste- rande materialet uppvärmdes 45 minuter med ättiksyraanhydrid och indunstades till torrhet. Vatten sattes till återstoden och blandningen alkaliserades med en vattenlösning av natrium- hydroxid. Det olösliga materialet tillvaratogs och tvättades med vatten för erhållande av 11,5 g (66,5 % utbyte) av 8-11- -ÅÄ-(2~pyrimidinyl)-1-piperazinylfbutylf-8-azaspiro¿§.57de- kan-7,9-dion i form av den fria basen med smältpunkten 90 - - 9s°.Analysis Ber. for C 13 H 21 N 4 -Br: C 49.85 H 6.76 N 17.89 Br 25.51% Found: C 50.03 H 6.87 N 17.84 Br 25.44% Example 5 8- [α-α2- (2-pyrimidinyl) -1-piperazinyl] -butyl] -8-azaspiro- ¿§.§Zdekan-7,9 ~ dion O N '° 3 (cx) cH-u ~ <> .z 22 z U R O Reaction in n-butanol - A mixture of 7.5 g (0.045 mol) 3,3-tetramethylene glutarimide, 15.4 g (0.045 mol) of 8- (2-pyrimethyl) dinyl) -8-aza-5-azoniaspirol.yydecane bromide and 6.2 g (0.045 mol) potassium carbonate in 250 ml of n-butanol was refluxed 21 hours, filtered and evaporated to dryness. The remaining The material was heated with acetic anhydride for 45 minutes and evaporated to dryness. Water was added to the residue and the mixture was alkalized with an aqueous solution of sodium hydroxide. The insoluble material was collected and washed with water to give 11.5 g (66.5% yield) of 8-11 -ÅÄ- (2-pyrimidinyl) -1-piperazinylphbutyl-8-azaspiro [.57de- can-7,9-dione in the form of the free base with melting point 90 - - 9s °.
Den fria basen upptogs i isopropanol och behandlades med kon- centrerad klorvätesyra, vilket gav hydroklorídsaltet. Kristal- lisation ur ísopropanol gav analytiskt ren 8-¿3-[1-(2-pyrimi- 447 257 dinyl)-l-piperazinyL7butyI7-8-azaspiroíß.§7dekan-7,9-dion- -hydroklorid.The free base was taken up in isopropanol and treated with centered hydrochloric acid to give the hydrochloride salt. Crystal Isolation of isopropanol gave analytically pure 8-β- [1- (2-pyrimidine) 447 257 dinyl) -1-piperazinyL7butyI7-8-azaspirois.§7decane-7,9-dione- hydrochloride.
Analys Ber. för C2lH3lN502-Hcl: C 59,77 H 7,65 N 16,60 Cl 8,40 % Funnet: C 60,07 H 7,72 N 16,74 Cl 8,27 % Omsättning i dimetylformamid - En blandning av 16,7 g (0,1 mol) 3,3-tetrametylenglutarimid, 29,9 g (0,1 mol) 8-(2-pyri- midinyl)-8-aza-5-azoniaspiro¿Z.åfdekan-bromid och 16,6 g (0,l2 mol) kaliumkarbonat i 190 ml dimetylformamid hölls vid 150-l55° under 24 timmar och indunstades därefter till torrhet under reducerat tryck. Det erhållna fasta materialet triture- rades med 90 ml vatten, upptogs i 10%-ig klorvätesyra och fil- trerades. Det sura filtratet alkaliserades med en 10%-ig vat- tenlösning av natriumhydroxid och den utfällda fria basen tillvaratogs och torkades för erhållande av 8-[Ä-[Ä-(2-PYri“ midinyl)-l-piperazinyL]butyL7-8-azaspiroll.åfdekan-7,9-dion.Analysis Ber. for C 21 H 31 N 5 O 2 -HCl: C 59.77 H 7.65 N 16.60 Cl 8.40% Found: C 60.07 H 7.72 N 16.74 Cl 8.27% Reaction in dimethylformamide - A mixture of 16.7 g (0.1 mol) 3,3-tetramethylene glutarimide, 29.9 g (0.1 mol) 8- (2-pyrimidine midinyl) -8-aza-5-azoniaspiro [z] decane bromide and 16.6 g (0.2 mol) of potassium carbonate in 190 ml of dimethylformamide was maintained 150-155 ° for 24 hours and then evaporated to dryness under reduced pressure. The resulting solid material is triturated. was eluted with 90 ml of water, taken up in 10% hydrochloric acid and filtered. trerades. The acidic filtrate was alkalized with a 10% aqueous solution. sodium hydroxide solution and the precipitated free base was collected and dried to give 8- [Ä- [Ä- (2-PYri midinyl) -1-piperazinyl] butyl [7-8-azaspirol] decane-7,9-dione.
Genom att följa förfarandet ovan men använda 27,3 g (0,1 mol) 8-(2-pyrimidinyl)-8-aza-5-azoniaspirojï.§7dekan-kloridmono- hydrat istället för motsvarande kvaternära bromid erhölls den i rubriken angivna föreningen i form av den fria basen i ett utbyte av ca. 80 % och med smältpunkten l00°.Following the procedure above but using 27.3 g (0.1 mol) 8- (2-Pyrimidinyl) -8-aza-5-azoniaspiroj.§7decan-chloride mono- hydrate instead of the corresponding quaternary bromide it was obtained the title compound in the form of the free base in one yield of approx. 80% and with a melting point l00 °.
Nedan följer en jämförelse mellan föreliggande uppfinning och den mest närliggande teknikens ståndpunkt, nämligen US 3 717 634, vilken jämförelse visar det synnerligen för- bättrade totalutbyte som uppnås enligt uppfinningen vid framställning av buspiron. ...m .u . 447 257 Föreliggande uppfinning 1) X-(CH2)2-X' GD »o~<;f¿----» we DC? -ww .Q-ëfg' n = 4 n = 5 Anm: Steg 1) 84 % 94 % Exempel 2, 4 Steg 2) 66,5 % Exempel 5 Total- utbyte 55'9 % ........-4.-.., . 447 257 N j) Hal(CH2)n.CN H H- '----------à H2!-(CH¿)¿-N “__ \_/- \_/,, 2) H2/Ra-Ni eller Nnznnz/Ra-Ni Dä _mz)n_ “O “_ Û Il n 4 n = 5 (n*= 3) (n'= 4) Anm: Steg l) 70 % 80 % Tab.III; sp ll/12 70 % 70 % H : förfarande 5A 2 Steg 2) 87 % 87 % NHZNHZ: förfarande 5B Steg 3) 67 % 52 % Tab.I; sp. 7/8 Total- 32,8 % 25,5 % Ra~Ni “tbYte 40.8 % 31,7 z NH -mz 2 2The following is a comparison between the present invention and the state of the art U.S. Pat. No. 3,717,634, which comparison shows the extremely improved overall yield achieved according to the invention at production of buspirone. ... m .u. 447 257 The present invention 1) X- (CH2) 2-X 'GD »O ~ <; f¿ ----» we DC? -ww .Q-ëfg ' n = 4 n = 5 Note: Step 1) 84% 94% Example 2, 4 Step 2) 66.5% Example 5 Total- yield 55'9% ........- 4 .- ..,. 447 257 N j) Hal (CH2) n.CN H H- '---------- à H2! - (CH¿) ¿-N “__ \ _ / - \ _ / ,, 2) H2 / Ra-Ni or Nnznnz / Ra-Ni Dä _mz) n_ “O “_ Û Il n 4 n = 5 (n * = 3) (n '= 4) Note: Step l) 70% 80% Tab.III; sp ll / 12 70% 70% H: Method 5A 2 Step 2) 87% 87% NH 2 NH 2: Process 5B Step 3) 67% 52% Tab.I; sp. 7/8 Total- 32.8% 25.5% Ra ~ Ni TbYte 40.8% 31.7 z NH -mz 2 2
Claims (4)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/197,416 US4351939A (en) | 1980-10-16 | 1980-10-16 | Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8600174D0 SE8600174D0 (en) | 1986-01-15 |
| SE8600174L SE8600174L (en) | 1986-01-15 |
| SE447257B true SE447257B (en) | 1986-11-03 |
Family
ID=22729338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8106060A SE439167B (en) | 1980-10-16 | 1981-10-13 | QUARTERLY SPIROAMMONIUM HALIDES, PROCEDURES FOR THEIR PREPARATION AND PROCEDURE FOR THE PREPARATION OF N- (2-PYRIMIDINYL) -PIPERAZINYLALKYL-AZASPIROAL CONDIONS |
| SE8600174A SE447257B (en) | 1980-10-16 | 1986-01-15 | PROCEDURE FOR THE PREPARATION OF N- (2-PYRIMIDINYL) -PIPERAZINYLALKYL-AZASPIROAL CONDION |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8106060A SE439167B (en) | 1980-10-16 | 1981-10-13 | QUARTERLY SPIROAMMONIUM HALIDES, PROCEDURES FOR THEIR PREPARATION AND PROCEDURE FOR THE PREPARATION OF N- (2-PYRIMIDINYL) -PIPERAZINYLALKYL-AZASPIROAL CONDIONS |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US4351939A (en) |
| JP (2) | JPS5724384A (en) |
| KR (2) | KR890000465B1 (en) |
| AT (1) | AT382153B (en) |
| AU (1) | AU524822B2 (en) |
| BE (1) | BE890509A (en) |
| CA (1) | CA1175832A (en) |
| CH (1) | CH647778A5 (en) |
| CY (1) | CY1325A (en) |
| DE (1) | DE3141256C2 (en) |
| DK (1) | DK148481C (en) |
| ES (2) | ES501994A0 (en) |
| FI (1) | FI75159C (en) |
| FR (1) | FR2492383A1 (en) |
| GB (1) | GB2085436B (en) |
| GR (1) | GR74687B (en) |
| HK (1) | HK35386A (en) |
| HU (2) | HU187999B (en) |
| IE (1) | IE51646B1 (en) |
| IL (1) | IL64047A (en) |
| IT (1) | IT1143244B (en) |
| KE (1) | KE3596A (en) |
| LU (1) | LU83657A1 (en) |
| MY (1) | MY8600475A (en) |
| NL (2) | NL179055C (en) |
| NZ (1) | NZ196974A (en) |
| OA (1) | OA06920A (en) |
| PT (1) | PT73824B (en) |
| SE (2) | SE439167B (en) |
| SG (1) | SG97885G (en) |
| SU (1) | SU1342420A3 (en) |
| YU (2) | YU42565B (en) |
| ZA (1) | ZA812759B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT387221B (en) * | 1980-09-08 | 1988-12-27 | Bristol Myers Co | METHOD FOR PRODUCING THE NEW |
| US4507303A (en) * | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
| US4452799A (en) * | 1981-12-23 | 1984-06-05 | Mead Johnson & Company | Benzisothiazole and benzisoxazole piperazine derivatives |
| JPS5945380U (en) * | 1982-09-20 | 1984-03-26 | いすゞ自動車株式会社 | Fixing device for vehicle strips |
| US5066783A (en) * | 1986-05-20 | 1991-11-19 | Cohen Eric A | Antiviral peptides and means for treating herpes infections |
| US4810789A (en) * | 1987-08-28 | 1989-03-07 | Bristol-Myers Company | Process for buspirone hydrochloride polymorphic crystalline form conversion |
| US5015646A (en) * | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
| US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
| FR2705098B1 (en) * | 1993-05-10 | 1995-08-04 | Esteve Labor Dr | Process for the preparation of 2- {4- [4- (chloro-1-pyrazolyl) butyl] 1-piperazinyl} pyrimidine (Lesopitron). |
| CA2146593A1 (en) * | 1994-05-05 | 1995-11-06 | Jack Melton | Large-scale process for azapirone synthesis |
| US5521313A (en) * | 1994-05-05 | 1996-05-28 | Bristol-Myers Squibb Company | Process for preparing certain azapirones |
| US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| TW200302728A (en) * | 2002-02-01 | 2003-08-16 | Novartis Ag | Substituted amines as IgE inhibitors |
| EP1919922B1 (en) * | 2005-08-30 | 2011-04-20 | Honeywell International Inc. | Method for synthesizing spiro quaternary ammonium systems |
| CN101089000B (en) * | 2006-06-16 | 2011-01-05 | 北京大学 | Spiro piperazine quaternary ammonium salt compound and its preparation method and application |
| CN101362751B (en) * | 2007-08-10 | 2011-05-11 | 成都科瑞德医药投资有限责任公司 | Tandospirone citrate, preparation method thereof, formulations and quality control method |
| WO2011136383A1 (en) * | 2010-04-26 | 2011-11-03 | Dainippon Sumitomo Pharma Co., Ltd. | A process of a quaternary ammonium salt |
| ES2527545T3 (en) * | 2010-04-26 | 2015-01-26 | Sumitomo Dainippon Pharma Co., Ltd. | A process of preparing a quaternary ammonium salt using phosphate |
| IT201900000657A1 (en) | 2019-01-16 | 2020-07-16 | Procos Spa | PROCESS FOR THE SYNTHESIS OF GEPIRONE |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB948730A (en) * | 1959-04-08 | 1964-02-05 | Wellcome Found | Substituted cyclopropanes and related compounds |
| US3968216A (en) * | 1969-10-29 | 1976-07-06 | Smith Kline & French Laboratories Limited | Method of inhibiting histamine activity with guanidine compounds |
| BE759371A (en) * | 1969-11-24 | 1971-05-24 | Bristol Myers Co | HETEROCYCLICAL AZASPIRODECANEDIONES AND METHODS FOR THEIR PREPARATION |
-
1980
- 1980-10-16 US US06/197,416 patent/US4351939A/en not_active Expired - Lifetime
-
1981
- 1981-04-27 ZA ZA00812759A patent/ZA812759B/en unknown
- 1981-04-28 YU YU1103/81A patent/YU42565B/en unknown
- 1981-04-30 NZ NZ196974A patent/NZ196974A/en unknown
- 1981-05-06 GR GR64860A patent/GR74687B/el unknown
- 1981-05-07 ES ES501994A patent/ES501994A0/en active Granted
- 1981-05-08 AU AU70292/81A patent/AU524822B2/en not_active Expired
- 1981-05-27 JP JP7944381A patent/JPS5724384A/en active Granted
- 1981-07-01 GB GB8120338A patent/GB2085436B/en not_active Expired
- 1981-07-01 CY CY1325A patent/CY1325A/en unknown
- 1981-08-11 CA CA000383588A patent/CA1175832A/en not_active Expired
- 1981-09-25 BE BE0/206077A patent/BE890509A/en not_active IP Right Cessation
- 1981-09-28 LU LU83657A patent/LU83657A1/en unknown
- 1981-09-30 DK DK433781A patent/DK148481C/en active
- 1981-10-12 OA OA57515A patent/OA06920A/en unknown
- 1981-10-12 FR FR8119153A patent/FR2492383A1/en active Granted
- 1981-10-13 IT IT49476/81A patent/IT1143244B/en active
- 1981-10-13 FI FI813178A patent/FI75159C/en not_active IP Right Cessation
- 1981-10-13 NL NLAANVRAGE8104660,A patent/NL179055C/en not_active IP Right Cessation
- 1981-10-13 SE SE8106060A patent/SE439167B/en not_active IP Right Cessation
- 1981-10-14 CH CH6580/81A patent/CH647778A5/en not_active IP Right Cessation
- 1981-10-14 IL IL64047A patent/IL64047A/en not_active IP Right Cessation
- 1981-10-15 HU HU843458A patent/HU187999B/en unknown
- 1981-10-15 PT PT73824A patent/PT73824B/en unknown
- 1981-10-15 IE IE2420/81A patent/IE51646B1/en not_active IP Right Cessation
- 1981-10-15 HU HU812982A patent/HU185967B/en not_active IP Right Cessation
- 1981-10-16 DE DE3141256A patent/DE3141256C2/en not_active Expired
- 1981-10-16 KR KR1019810003924D patent/KR890000465B1/en active
- 1981-10-16 KR KR8103924A patent/KR870000321B1/en not_active IP Right Cessation
- 1981-10-16 AT AT0444681A patent/AT382153B/en not_active IP Right Cessation
-
1982
- 1982-04-01 ES ES511079A patent/ES8304967A1/en not_active Expired
-
1983
- 1983-03-09 SU SU833562184A patent/SU1342420A3/en active
- 1983-06-21 YU YU1360/83A patent/YU43316B/en unknown
-
1985
- 1985-05-17 NL NL8501430A patent/NL8501430A/en active Search and Examination
- 1985-12-17 JP JP60282152A patent/JPS61178983A/en active Granted
- 1985-12-23 SG SG978/85A patent/SG97885G/en unknown
-
1986
- 1986-01-13 KE KE3596A patent/KE3596A/en unknown
- 1986-01-15 SE SE8600174A patent/SE447257B/en not_active IP Right Cessation
- 1986-05-22 HK HK353/86A patent/HK35386A/en not_active IP Right Cessation
- 1986-12-30 MY MY475/86A patent/MY8600475A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE447257B (en) | PROCEDURE FOR THE PREPARATION OF N- (2-PYRIMIDINYL) -PIPERAZINYLALKYL-AZASPIROAL CONDION | |
| RU2605551C2 (en) | Salts of 4-methyl-n-[3-(4-methylimidazole-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridine-3-ylpyrimidine-2-ylamino)benzamide | |
| FI111641B (en) | Process for the preparation of arylpiperazinyl heterocyclic compounds | |
| JP2018150383A (en) | Method for preparing methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and method for purifying the same for use as pharmaceutically active compound | |
| SK287424B6 (en) | Lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)- 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof | |
| US4417049A (en) | Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process | |
| US20090299064A1 (en) | Methods and intermediates for the preparation of optionally radio-labeled imatinib | |
| NO147838B (en) | INTERMEDIATE FOR USE IN PREPARATION OF THE HYPOTENSIVE AGENT 2- (4- (2-FUROYL) PIPERAZIN-1-YL) -4-AMINO-6,7-DIMETOXYKINAZOLINE | |
| NO321357B1 (en) | Process for Preparation of 4- (heteroarylmethyl) -halo-1 (2H) -phthalazinones | |
| US5708172A (en) | Intermediates for synthetic use and processes for producing aminopiperazine derivatives | |
| JPH06100540A (en) | 5-isoquinolinesulfonic acid amide derivative | |
| CN109748885B (en) | Ceritinib intermediate and preparation method of ceritinib | |
| NO116853B (en) | ||
| JPH0113476B2 (en) | ||
| SU999967A3 (en) | Process for producing 6-n-substituted 6-amino-3-pyridazinyl hydrizines or their salts | |
| DK171253B1 (en) | Process for Preparation of 5-Q- [3,4-Bipyridine] -6 (1H) -one | |
| EP0199485B1 (en) | Intermediates and process | |
| CA2098982A1 (en) | Indolizine derivatives, process of preparation and use for the preparation of aminoalkoxybenzenesulphonylindolizine compounds with pharmaceutical activity | |
| RU1799381C (en) | Method of 8 | |
| JP2018509467A (en) | Salt form, crystal form of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method and intermediate thereof | |
| US20040157821A1 (en) | Sulfate of cephem compound | |
| CN115850178A (en) | Preparation method of 1-methyl-3- (trifluoromethyl) -1H-pyrazole-5-alcohol | |
| SU247954A1 (en) | METHOD OF OBTAINING? YAS- (PIRIMIDINYL) -ALCANES | |
| AU622332B2 (en) | New azetidines, their preparation and their application as intermediates for the preparation of compounds with antimicrobial activity | |
| JPS63301863A (en) | Isoindoline derivative, novel intermediate thereof and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Application for supplementary protection certificate filed |
Free format text: 8600174 |
|
| SPCG | Supplementary protection certificate granted |
Free format text: 8600174, EXPIRES: 20060704 |
|
| NAL | Patent in force |
Ref document number: 8600174-0 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8600174-0 Format of ref document f/p: F |